Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …

Immunotherapy has revolutionized the clinical management of many malignancies but is
infrequently associated with durable objective responses when used as a standalone …

Background Immunotherapy has determined unprecedented long-term responses in several
hematological and solid tumors. In the MOUSEION-03 study, we conducted a meta-analysis …

Targeted immunotherapy has improved patient survival in head and neck squamous cell
carcinoma (HNSCC), but less than 20% of patients produce a durable response to these …

In the setting of conventional radiation therapy, even when combined with immunotherapy,
head and neck cancer often recurs locally and regionally. Elective nodal irradiation (ENI) is …

The progression of cancer involves a critical step in which malignant cells escape from
control by the immune system. Antineoplastic agents are particularly efficient when they …

ECOG performance status (PS) is a pivotal prognostic factor in a wide number of solid
tumors. We performed a meta-analysis to assess the role of ECOG PS in terms of survival in …

Immune checkpoint blockade (ICB) immunotherapy is a first-line treatment for selected
cancers, yet the mechanisms of its efficacy remain incompletely understood. Furthermore …

Most patients diagnosed with head and neck squamous cell carcinoma (HNSCC) will
present with locally advanced disease, requiring multimodality therapy. While this approach …

Owing to advances in radiotherapy, the physical properties of radiation can be optimized to
enable individualized treatment; however, optimization is rarely based on biological …